Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member] Private Placement [Member]	Common Stock [Member] A T M Offering [Member]	Common Stock [Member]	AOCI Attributable to Parent [Member] Private Placement [Member]	AOCI Attributable to Parent [Member] A T M Offering [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member] Private Placement [Member]	Retained Earnings [Member] A T M Offering [Member]	Retained Earnings [Member]	Private Placement [Member]	A T M Offering [Member]	Total
Balances (in shares) at Dec. 31, 2023			37,958,000
Balances at Dec. 31, 2023			$ 166,609			$ 6			$ (115,558)			$ 51,057
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			5,916
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Share-based compensation expense			488			0			0			488
Unrealized gain (loss) on marketable securities			0			(45)			0			(45)
Net loss			$ 0			0			(5,151)			(5,151)
Balance (in shares) at Mar. 31, 2024			37,963,916
Balance at Mar. 31, 2024			$ 167,097			(39)			(120,709)			46,349
Balances (in shares) at Dec. 31, 2023			37,958,000
Balances at Dec. 31, 2023			$ 166,609			6			(115,558)			$ 51,057
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)												17,747
Issuance of common shares upon the exercise of stock options (in shares)												70,750
Unrealized gain (loss) on marketable securities												$ 75
Net loss												(16,544)
Balance (in shares) at Sep. 30, 2024			42,766,497
Balance at Sep. 30, 2024			$ 179,985			81			(132,102)			47,964
Balances (in shares) at Mar. 31, 2024			37,963,916
Balances at Mar. 31, 2024			$ 167,097			(39)			(120,709)			46,349
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			5,916
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Issuance of common shares upon the exercise of stock options (in shares)			2,750
Issuance of common shares upon the exercise of stock options			$ 7			0			0			7
Share-based compensation expense			443			0			0			443
Unrealized gain (loss) on marketable securities			0			(12)			0			(12)
Net loss			$ 0			0			(5,119)			(5,119)
Issuance of common shares (in shares)	4,720,000
Issuance of common shares	$ 11,747			$ 0			$ 0			$ 11,747
Balance (in shares) at Jun. 30, 2024			42,692,582
Balance at Jun. 30, 2024			$ 179,294			(51)			(125,828)			53,415
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			5,915
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Issuance of common shares upon the exercise of stock options (in shares)			68,000
Issuance of common shares upon the exercise of stock options			$ 126			0			0			126
Share-based compensation expense			565			0			0			565
Unrealized gain (loss) on marketable securities			0			132			0			132
Net loss			$ 0			0			(6,274)			(6,274)
Balance (in shares) at Sep. 30, 2024			42,766,497
Balance at Sep. 30, 2024			$ 179,985			81			(132,102)			47,964
Balances (in shares) at Dec. 31, 2024			42,818,660
Balances at Dec. 31, 2024			$ 180,697			23			(140,002)			40,718
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			3,805
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Issuance of common shares upon the exercise of stock options (in shares)			37,000
Issuance of common shares upon the exercise of stock options			$ 94			0			0			94
Share-based compensation expense			867			0			0			867
Unrealized gain (loss) on marketable securities			0			(18)			0			(18)
Net loss			$ 0			0			(7,707)			(7,707)
Balance (in shares) at Mar. 31, 2025			42,859,465
Balance at Mar. 31, 2025			$ 181,658			5			(147,709)			33,954
Balances (in shares) at Dec. 31, 2024			42,818,660
Balances at Dec. 31, 2024			$ 180,697			23			(140,002)			$ 40,718
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)												11,412
Issuance of common shares upon the exercise of stock options (in shares)												275,125
Unrealized gain (loss) on marketable securities												$ 27
Net loss												$ (24,026)
Issuance of common shares in settlement of deferred stock units (in shares)												142,345
Issuance of common shares (in shares)											223,472
Balance (in shares) at Sep. 30, 2025			52,077,439
Balance at Sep. 30, 2025			$ 215,600			50			(164,028)			$ 51,622
Balances (in shares) at Mar. 31, 2025			42,859,465
Balances at Mar. 31, 2025			$ 181,658			5			(147,709)			33,954
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			3,803
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Issuance of common shares upon the exercise of stock options (in shares)			66,875
Issuance of common shares upon the exercise of stock options			$ 163			0			0			163
Share-based compensation expense			771			0			0			771
Unrealized gain (loss) on marketable securities			0			(19)			0			(19)
Net loss			$ 0			0			(7,699)			(7,699)
Issuance of common shares in settlement of deferred stock units (in shares)			142,345
Balance (in shares) at Jun. 30, 2025			43,072,488
Balance at Jun. 30, 2025			$ 182,592			(14)			(155,408)			27,170
Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)			3,804
Issuance of common shares upon the vesting and settlement of restricted stock units			$ 0			0			0			0
Issuance of common shares upon the exercise of stock options (in shares)			171,250
Issuance of common shares upon the exercise of stock options			$ 465			0			0			465
Share-based compensation expense			1,016			0			0			1,016
Unrealized gain (loss) on marketable securities						64						64
Net loss			$ 0			0			(8,620)			(8,620)
Issuance of common shares (in shares)	8,606,425	223,472
Issuance of common shares	$ 29,977	$ 1,550		$ 0	$ 0		$ 0	$ 0		$ 29,977	$ 1,550
Balance (in shares) at Sep. 30, 2025			52,077,439
Balance at Sep. 30, 2025			$ 215,600			$ 50			$ (164,028)			$ 51,622

DiaMedica Therapeutics Inc. 10-Q